SoFi Technologies Inc vs GeneDx Holdings Corp — how do they compare? SoFi Technologies Inc trades at $17.66 (market cap $21.82B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: SoFi Technologies Inc is far larger — about 12.1× GeneDx Holdings Corp's market cap. Which is the better fit depends on your goals.
| SOFI | WGS | |
|---|---|---|
Market Cap | $21.82B | $1.80B |
Sector | Financials | Technology |
52-Week High | $32.21 | $167.51 |
52-Week Low | $15.15 | $34.51 |
Enterprise Value | — | $1.80B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% amid a bearish technical signal and negative profitability. Recent earnings showed a Q1 2026 miss after two prior beats, with revenue growth but widening losses projected for 2026. The stock faces significant headwinds from multiple securities class action lawsuits alleging misrepresentations, with a deadline of August 3, 2026.
Despite a high analyst buy consensus (90.9%) and a $75.40 price target implying 24% upside, risks are elevated due to litigation, negative margins, and a high EV/EBITDA of 161.17. The upcoming Q2 2026 results on August 3 will be critical for investor confidence, but the legal overhang and fundamental challenges suggest cautious near-term outlook.
Trailing returns across standard periods
Latest headlines on both assets
SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →